Frontline Plc Ordinary Shares vs Vir Biotechnology Inc. Common Stock — how do they compare? Frontline Plc Ordinary Shares trades at $54.64 (market cap $13.14B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Frontline Plc Ordinary Shares is far larger — about 7.3× Vir Biotechnology Inc. Common Stock's market cap, and Frontline Plc Ordinary Shares pays a 9.11% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Frontline Plc Ordinary Shares for 1 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| FRO | VIR | |
|---|---|---|
Market Cap | $13.14B | $1.80B |
Volume | 3,351,547 | 1,782,836 |
Sector | Industrials | Health |
52-Week High | $59.19 | $11.78 |
52-Week Low | $20.58 | $5.12 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $15.26B | $1.36B |
Dividend Yield | 9.11% | — |
Signals from Pluang's Aura AI — not financial advice
Frontline (FRO) trades at $59.04, down 0.25% on the day, but maintains a strong technical and fundamental position. The stock is near its 52-week high, supported by bullish moving averages and robust earnings, with Q2 2026 EPS beating estimates at $2.96. Revenue and profitability have surged, with 2026 net income margin projected at 54.75%. Recent news highlights a special dividend declaration and institutional buying interest.
The outlook for FRO is positive, driven by record earnings and favorable shipping market dynamics. Investment opportunities include strong cash flow generation and shareholder returns, but risks involve exposure to volatile freight rates and geopolitical tensions affecting global trade. Analyst sentiment is mixed, with a 'Hold' consensus suggesting cautious optimism amid near-term highs.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Frontline operates a fleet of oil tankers that transport crude oil by sea. Its vessels serve global energy trading routes.
Read more on FRO →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →